{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ebe8cc563e3d811bbd2c9d8/6afc7f9827224dadcedd5dec?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"What is on the horizon for BCMA-directed ADCs in MM? ","description":"<p>The Multiple Myeloma Hub spoke with Marc Raab, Heidelberg University Hospital, DE. We asked, What is on the horizon for BCMA-directed antibody–drug conjugates in multiple myeloma? </p><p><br></p><p>In this interview, Raab discusses the ongoing development of belantamab mafodotin in additional combination regimens and earlier lines of therapy, as well as investigational antibody–drug conjugates (ADCs) incorporating alternative cytotoxic payloads or targeting other antigens. Raab also explores the potential role of ADC-based regimens for patients who are ineligible for, or have previously received, chimeric antigen receptor (CAR) T-cell therapy or bispecific antibodies. </p><p><br></p><p><em>This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.</em> </p>","author_name":"Scientific Education Support"}